In this study, we investigated the effects of the
cyclooxygenase (COX)-2 selective inhibitor,
meloxicam, on
cisplatin-induced
inflammation, oxidative stress and renal lesions in BALB/c mice. A single
cisplatin injection (13 mg/kg, i.p.) significantly increased plasma
creatinine, blood
urea nitrogen and urinary
glucose accompanied by a concomitant increase in COX-2
mRNA and COX-2
protein levels. These changes in renal lesion parameters were diminished by simultaneous treatment of
meloxicam (0.7 mg/kg/day in
drinking water). The expression of oxidative stress markers, p47(
phox), p67(
phox), hemoxygenase-1 (HO-1),
nicotinamide adenine dinucleotide phosphate (
NADPH) oxidase 2 (NOX2) and
4-hydroxy-2-nonenal (4-HNE)-modified
protein were increased with
cisplatin injection. Simultaneous treatment of
meloxicam with
cisplatin significantly inhibited the increase in p47(
phox), HO-1 and 4-HNE-modified
protein. The phosphorylation of extracellular regulated
kinase (ERK) and
c-jun-N-terminal kinase (JNK) were increased with
cisplatin injection, but these changes were inhibited by
meloxicam. Moreover, concomitant
meloxicam treatment also prevented the
cisplatin-induced infiltration of macrophages to the tubulointerstitial area. These results suggest that
meloxicam can ameliorate
cisplatin-induced mouse renal lesions, potentially through the inhibition of inflammatory and oxidative stress responses.